E E Sercarz’s research while affiliated with La Jolla Institute for Allergy & Immunology and other places

Adaptive immune responses are regulated by many different molecular and cellular effectors. Regulator T cells are coming to their rights again, and these T cells seem to have ordinary alpha/beta T-cell receptors (TCRs) and to develop in the thymus. Autoimmune responses are tightly regulated by such regulatory T cells, a phenomenon which is beneficial to the host in autoimmune situations. However, the regulation of autoimmune responses to tumour cells is harmful to the host, as this regulation delays the defence against the outgrowth of neoplastic cells. In the present review, we discuss whether regulatory T cells are specific for antigen and/or for antigen receptors. Our interest in these phenomena comes from the findings that T cells produce many more TCR-alpha and TCR-beta chains than are necessary for surface membrane expression of TCR-alphabeta heterodimers with CD3 complexes. Excess TCR chains are degraded by the proteasomes, and TCR peptides thus become available to the assembly pathway of major histocompatibility complex class I molecules. Consequently, do T cells express two different identification markers on the cell membrane, the TCR-alphabeta clonotype for recognition by B-cell receptors and clonotypic TCR-alphabeta peptides for recognition by T cells?

The first half of the 20th century saw a revelation in our understanding of the exquisite specificity of antibodies, best exemplified in the work by Karl Landsteiner. A single substituent on a hapten could be readily distinguished from a closely related one by an animal’s antiserum. The various antibodies in that antiserum, with their unique perspectives of these cross-reactive haptens/determinants, combined to provide an unmistakable portrait of each region of the antigen. Of course, some antibodies overlapped with others so that, in a sense, a continuum of antibody footprints could be drawn covering the structure.

T lymphocytes play a central role in the pathogenesis of a large number of human conditions including autoimmunity and graft rejection. Although T cells are key players in mounting immune responses, the assessment of T cell repertoires has yet to find an important role in clinical decision making. In this review, we discuss the "immunoscope" technique and its potential diagnostic role in a variety of clinical scenarios. This is an RT-PCR based approach that subdivides a bulk T cell population (i. e. from blood, lymph, spleen, or tissue) into approximately 2800 groups based upon rearranged variable beta (Vbeta)/joining beta (Jbeta) gene segments and the resulting length of the T cell receptor's (TCR's) third complementarity determining region (CDR-3). This extensive subdivision, or focusing, allows clonal expansions to be directly observed. Such a fine-tuned analysis has revealed previously unappreciated aspects of the T cell repertoire. For instance, an antigen-specific immune response can be divided into both public and non-public components. The non-public repertoire contains the majority of the expanding T cells which are unique to the individual (private), or shared by only some (semi-private), while "public" T cells can be found responding to the antigenic determinant in every individual. Although they are often a minority of the response, the public T cell repertoire seems to play a more important role in defining, as well as driving, the overall immune phenotype in the animal. Immunoscope analysis has identified public and non-public responses in human pathologies, such as multiple sclerosis. The ability to characterize the driver T cells dictating the state of immunity/autoimmunity in individual patients will be an important step towards understanding autoimmunity and designing effective treatment for a variety of conditions including rheumatoid arthritis and multiple sclerosis. We review the current literature involving public and non-public repertoires and discuss the prospect that immunoscope analysis may play a central role in the study and perhaps the management of human autoimmune diseases, and cancer.

The considerable breadth of the self-directed T cell repertoire has only fully been appreciated during this past decade. It is a potential repertoire which can be tapped in various ways, most evidently in the study of autoimmune diseases, when because of a variety of factors, there is enhanced processing and presentation of determinants on self antigens. In this review, we have focused on the engagement of this self-reactive repertoire and some of the rules involved, which are not always so obvious. The total "residual" self-reactive repertoire directed against a single antigen (that remains after negative selection) will be a heterogeneous assemblage of T cells - (a) high affinity T cells directed against determinants whose presentation during tolerance induction was prevented, eg. through competitive binding by neighboring determinants; (b) lower affinity T cells directed against well-presented (dominant), as well as poorly-presented (cryptic) determinants; and (c) high affinity T cells directed against poorly-presented determinants, which are only presented during inflammation. Under conditions that favor upregulation of previously cryptic self determinants, one or more of the above subsets of the 'protected' T cell repertoires can be stimulated by these self determinants, leading to induction of autoreactivity. The latter could eventually result in autoimmunity under permissive conditions governed by MHC and non-MHC genes. Interestingly, the very same repertoires that appear to be recruited into pathogenic autoimmune destruction may be alternatively manipulated as a source of anti-cancer treatment. It is now evident that many tumor antigens are unmutated self antigens, and cryptic determinants within such tumor antigens could be used to recruit the anticryptic T cell repertoire for induction of anti-tumor immunity.

Autoimmune diseases are often characterized by spontaneous remission followed by relapses. Although the mechanism(s) controlling pathogenic self-reactive T cells are not fully understood, recent data in experimental autoimmune encephalomyelitis (EAE), a prototype for CD4 T cell-mediated autoimmune diseases, indicate that spontaneous recovery is mediated by regulatory T cells (Treg) specific for peptides derived from the beta-chain of the TCR. Here we have tested whether recombinant single-chain TCRs (scTCRs) containing Vbeta domains can be used as vaccines for efficient priming of Treg. A single injection of mice with these recombinant proteins leads to efficient in vivo priming of Treg and almost complete protection from Ag-induced EAE. Significantly, administration of scTCRs during ongoing disease at a 10-fold lower dose than that required for prophylactic treatment also reverses established EAE. However, if a higher dose of scTCR is administered during ongoing disease, paralytic symptoms become exacerbated and the majority of treated animals die from severe and chronic EAE. Furthermore, we demonstrate that regulatory determinants are processed and presented from scTCRs resulting in the recruitment of both CD4 and CD8 regulatory T cells which are required for efficient regulation induced by scTCR. Reversal of established disease following an optimum dose of recombinant TCRs suggests that proteins expressing appropriate Vbeta domains could be used for the treatment of a variety of T cell-mediated pathologic conditions.

T cell responses to different protein Ags have been shown to focus on a few ("immunodominant") determinants. We have addressed three major, interrelated questions regarding immunodominance. First, can each area within hen eggwhite lysozyme (HEL) serve as an immunodominant focus in different inbred mouse strains or are there structural constraints that limit the utilization of certain segments of the molecule? Second, in MHC-congenic mice with identical non-MHC genes, is response to HEL restricted to one or more members of a set of HEL determinants owing to processing constraints imposed by the background genes? Third, does a truncated TCR repertoire influence the immunodominance of certain determinants of HEL? Our results in 19 strains of mice, representing 11 different MHC haplotypes, demonstrate that the immunodominant determinants within HEL are distributed all over the molecule, suggesting that there is no inherent structural constraint imposed on certain regions to be always immunorecessive. However, in different mouse strains, the emergence of identical regions of HEL as immunodominant sites strictly correlates with the identity of their MHC haplotypes but not genetic background (non-MHC) genes. We attribute this relationship to "MHC-guided processing" of native Ag. Finally, our results demonstrate that a truncated TCR repertoire can result not only in the loss of response to certain immunodominant determinants, but can also result in a gain. These results should contribute significantly to further understanding of the mechanism of immunodominance.

The hierarchy of display of determinants on a protein antigen is of critical importance with respect to which T cells will be selected during thymic development, as well as in the induction of mature responses. Activation of T cells will be dependent on unfolding, reduction and chain cleavage of the antigen, and the vagaries of competition with other determinants as well as hindrance in access to the major histocompatibility complex (MHC) or subsequently of the MHC/peptide complex to the T cell receptor. We here focus on a description of the parameters that determine the generation and display of determinants on MHC class II molecules by different types of antigen presenting cells in different locations.